Jan 09, 2024 / 07:15PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Welcome to the Bayer session at the 42nd JPMorgan Health Care Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to welcome the CEO of the Pharma business at Bayer Stefan Orrick, who's going to present to us. We'll take questions after his presentation. So just please put your hand up, and we'll get a mic to you. Stefan, welcome to the conference.
Stefan Oelrich - Bayer Aktiengesellschaft - Head of the Pharmaceuticals Division & Member of the Board of Management
Well, thank you, Richard, and thank you for your interest in our business here, glad to see that the room is filling up fast. So I'm going to give you a little overview on how we're proceeding well with the implementation of our strategy. But before I get to that, we're really excited this week because we've had tremendous news flow with our latest Phase III trial, giving positive primary and secondary endpoints in 2 parallel trials, an approval for EYLEA in Europe, which was sort of
Bayer AG at JPMorgan Healthcare Conference Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers